Gout | Clinical
Gout Clinical Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
www.pharmacytimes.comHere are the latest high-level updates on gout.
-
Recent developments include new urate-lowering therapies and fixed-dose combination options that aim to simplify long-term management for hyperuricemia and gout, with regulatory activity reported in 2024–2025 timelines. This reflects ongoing efforts to expand treatment choices for patients who don’t reach target uric acid levels with allopurinol alone.[1][2]
-
Updated clinical guidance in the past year emphasizes starting anti-inflammatory treatment (NSAIDs, colchicine, or steroids) for acute flares and using urate-lowering therapy (ULT) to prevent future episodes, with attention to individual risk factors and comorbidities. Some reviews also highlight the importance of initiating ULT concomitantly with flare-prophylaxis to reduce flare risk in the first six months.[2]
-
Epidemiology and research trends show increasing attention to early-onset gout and the integration of newer diagnostic approaches and biomarkers, along with AI-enabled research tools in imaging and analytics. A number of 2025–2026 review articles summarize these advances and their implications for diagnosis and treatment.[3][4]
If you’d like, I can narrow this to:
- A quick summary of what changed in guidelines in 2025
- Specific new drugs approved in 2024–2025
- Practical tips for managing flares and starting ULT in primary care
Would you prefer a concise bullet list or a short comparative table of the new therapies and their key features? I can also pull more targeted regional news (e.g., U.S. vs Europe) if that helps.